With long-read sequencing, mapping, and other approaches, researchers assembled a high-quality genome for Aedes aegypti, a notorious infectious disease vector.
Fresh off its August IPO, the company reported $2.8 million in revenue for the quarter, up from $2.7 million a year ago.
The VGP released its first 15 high-quality reference genome assemblies today, which are part of the project's first phase to sequence 260 vertebrate genomes.
Using Hi-C, genome sequencing, and optical mapping, researchers profiled structural variants in multiple cancer cell lines, leading to potential non-coding drivers.
The company's offering of 3.36 million units at $6.125 per unit — each consisting of one share of common stock and one warrant — is expected to close Aug. 23.
The company plans to offer nearly 2.5 million units at a price of $6.00 to $7.00 per unit, which at the midpoint of the range would raise about $16 million.
In 2017, Bionano had $9.5 million in revenues and a net loss of 23.4 million, or $7.66 per share.
With its Direct Labeling and Staining (DLS) chemistry, currently available to early-access users, Bionano is pushing forward with more contiguous genome maps.
At PAG, researchers from the Rockefeller University Vertebrate Genome Laboratory outlined sequencing and assembly strategies for phase 1 of the VGP G10K.
After more than two years of development, the British vendor has matched HPC for sequencing alignment accuracy, at far lower power consumption.
The United Nations is to consider a ban on field testing gene drives at a meeting being held next week, Technology Review reports.
The Associated Press reports that gene-edited food may soon be for sale.
The US Department of Health and Human Services is beginning a series of meetings on human fetal tissue research, Stat News reports.
In Cell this week: epigenetic change linked to glioblastomas, rare and low-frequency variants contributing to multiple sclerosis risk, and more.